Madrigal Pharmaceuticals (MDGL) Other Operating Expenses (2023 - 2026)

Madrigal Pharmaceuticals (MDGL) has 4 years of Other Operating Expenses data on file, last reported at -$350.4 million in Q1 2026.

• Other Operating Expenses for Q1 2026 came in at -$350.4 million, down 68.82% year-over-year; the trailing twelve-month figure through Mar 2026 was -$549.7 million (down 808.31% YoY), and the FY2025 annual result was $56.1 million, up 800.82% from the prior year.
• Other Operating Expenses fell to -$350.4 million in Q1 2026 per MDGL's latest filing, from $24.4 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $497.1 million in Q4 2024 and troughed at -$350.4 million in Q1 2026.
• A 4-year average of -$78.7 million and a median of -$174.2 million in 2024 frame the typical range for Other Operating Expenses.
• On a YoY basis, Other Operating Expenses climbed as much as 110.4% in 2025 and fell as far as 95.08% in 2025.
• A 4-year view of Other Operating Expenses shows it stood at -$98.5 million in 2023, then jumped by 604.49% to $497.1 million in 2024, then sank by 95.08% to $24.4 million in 2025, then slumped by 1533.11% to -$350.4 million in 2026.
• Business Quant data shows MDGL's Other Operating Expenses at -$350.4 million in Q1 2026, $24.4 million in Q4 2025, and $18.1 million in Q3 2025.